BioCentury
ARTICLE | Clinical News

Biosimilar insulin glargine regulatory update

August 8, 2016 7:00 AM UTC

Merck is partnered with Samsung Bioepis Co. Ltd., a JV between Biogen and Samsung Biologics, to develop and commercialize multiple biosimilars, including MK-1293 (see BioCentury, Feb. 17, 2014). Samsung Biologics is a JV between Samsung Group and Quintiles Transnational Corp. (NYSE:Q, Research Triangle Park, N.C.). ...